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Introduction
Schizophrenia is a devastating psychiatric disorder with a 
median lifetime prevalence of 0.7%–0.8%,1 and the etiopatho-
genesis of this disorder is still unknown.2 One-carbon metab-
olism is a process whereby folate transfers one-carbon groups 
in a range of biological processes, including DNA synthesis 
and methylation and homocysteine metabolism.3 Growing 
evidence indicates that alterations in one-carbon metabolism 
may play an important role in schizophrenia pathogenesis.4,5
To date, we have investigated potential associations be-
tween one-carbon metabolism factors and schizophrenia risk. 
For example, we observed elevated blood homocysteine 
 levels in individuals with schizophrenia and provided evi-
dence of a causal relationship between elevated blood homo-
cysteine levels and schizophrenia risk.6,7 In addition, we 
showed that the methylenetetrahydrofolate reductase 
(MTHFR) C677T polymorphism, which causes reduced en-
zyme activity and elevated homocysteine levels, and com-
mon polygenic variants that are associated with plasma 
homo cysteine levels are risk factors for schizophrenia in the 
Japanese population.6,8 Furthermore, we showed aberrant 
DNA methylation in patients with schizophrenia, not only in 
peripheral leukocytes but also in the postmortem dorsolat-
eral prefrontal cortex.9–11
Vitamin B6 is a key component in one-carbon metab-
olism, in which homocysteine enters the transsulfuration 
pathway that leads to the production of cysteine and gluta-
thione. The first enzyme in this pathway is cystathionine 
β-synthase, which catalyzes the conversion of serine and 
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Background: Alterations in one-carbon metabolism have been associated with schizophrenia, and vitamin B6 is one of the key com-
ponents in this pathway. Methods: We first conducted a case–control study of serum pyridoxal levels and schizophrenia in a large 
 Japanese cohort (n = 1276). Subsequently, we conducted a meta-analysis of association studies (n = 2125). Second, we investigated 
whether rs4654748, which was identified in a genome-wide association study as a vitamin B6-related single nucleotide polymorphism, 
was genetically implicated in patients with schizophrenia in the Japanese population (n = 10 689). Finally, we assessed the effect of 
 serum pyridoxal levels on schizophrenia risk using a Mendelian randomization (MR) approach. Results: Serum pyridoxal levels were 
significantly lower in patients with schizophrenia than in controls, not only in our cohort, but also in the pooled data set of the meta- 
analysis of association studies (standardized mean difference –0.48, 95% confidence interval [CI] –0.57 to –0.39, p = 9.8 × 10–24). We 
failed to find a significant association between rs4654748 and schizophrenia. Furthermore, an MR analysis failed to find a causal rela-
tionship between pyridoxal levels and schizophrenia risk (odds ratio 0.99, 95% CI 0.65–1.51, p = 0.96). Limitations: Food consumption 
and medications may have affected serum pyridoxal levels in our cross-sectional study. Sample size, number of instrumental variables 
and substantial heterogeneity among patients with schizophrenia are limitations of an MR analysis. Conclusion: We found decreased 
serum pyridoxal levels in patients with schizophrenia in this observational study. However, we failed to obtain data supporting a causal 
relationship between pyridoxal levels and schizophrenia risk using the MR approach.
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homocysteine to cystathionine and water, and requires vita-
min B6 as a cofactor.5 To date, several cross-sectional 
 studies have shown decreased serum pyridoxal levels (1 of 
the 3 forms of vitamin B6) in individuals with schizophrenia 
compared with controls.12–15 However, the sample size of 
these studies was small (total number of participants of 
each study ≤ n = 377), and a meta-analysis of association 
studies between serum pyridoxal levels and schizophrenia 
was not performed. Furthermore, it is still unclear whether 
pyridoxal levels are causally related to schizophrenia be-
cause of confounding factors and reverse causality in obser-
vational epidemiological studies.
In this study, we first investigated whether serum pyri-
doxal levels differed between patients with schizophrenia and 
nonpsychiatric controls in a large Japanese cohort (n = 1276). 
Subsequently, we conducted a meta-analysis of association 
studies between serum pyridoxal levels and schizophrenia 
(n = 2125). Second, we investigated whether rs4654748 in 
the neuroblastoma breakpoint family member 3 (NBPF3) 
gene, which was identified in a genome-wide association 
study (GWAS) as a vitamin B6–related single nucleotide 
polymorphism (SNP),3 was genetically implicated in 
schizophrenia in the Japanese population (n = 10 689). 
 Finally, we assessed the effect of serum pyridoxal levels on 
schizophrenia risk using a Mendelian randomization (MR) 
approach, a useful tool for assessing causal associations in 
observational data.16 To show causality between serum 
pyridoxal levels and schizophrenia is important for under-
standing schizophrenia pathology and treatment, and an 
MR method, which utilizes genetic variants as instrumen-
tal variables for exposures of interest, can overcome prob-
lems in epidemiological studies, such as confounding and 
reverse  causality.17
Methods
Participants in an association study of serum pyridoxal 
levels and schizophrenia
A total of 365 patients with schizophrenia (213 men, mean 
age 58.7 ± 9.5 yr; 152 women, mean age 59.6 ± 9.7 yr) were re-
cruited from Tokushima University Hospital in Japan. 
Schizophrenia was diagnosed by at least 2 expert psych-
iatrists who used criteria listed in the DSM-IV based on ex-
tensive clinical interviews and a review of medical records. 
None of the patients exhibited any psychiatric comorbidity or 
cardiovascular disease. Most patients were being treated 
with various antipsychotic drugs. The median chlorproma-
zine equivalent dose was 550 mg/d (range 0 mg/d to 
3450 mg/d). In addition, 911 control participants (297 men, 
mean age 38.7 ± 12.4 yr; 614 women, mean age 42.9 ± 12.0 yr) 
were selected from volunteers without structured interviews, 
who were recruited among hospital staff, students and com-
pany employees and who were documented to be free of 
psychiatric problems and without a history of mental illness. 
All study participants were of Japanese origin. The study 
protocol was approved by the institutional ethics committee 
of the University of Tokushima Graduate School, and all 
 enrolled participants provided their written informed con-
sent for participation. This experiment was performed in ac-
cordance with the Committee’s guidelines. Of the 1276 par-
ticipants in this association study, 1224 provided genomic 
DNA (365 patients and 859 controls) for a genetic association 
study as described below.
Participants in a genetic association study between 
rs4654748 and schizophrenia
Four case–control sets were prepared from different facilities: 
the Tokushima University sample set (936 patients and 
2440 controls), the Riken sample set (2004 patients and 
2170 controls), the Osaka University sample set (451 patients 
and 602 controls), and the Fujita Health University sample set 
(1258 patients and 828 controls (Appendix 1, Table S1, avail-
able at jpn.ca/170053-a1). All study participants were of 
 Japanese origin. The study protocol was approved by the in-
stitutional ethics committees of all participating institutes, 
and all enrolled participants provided written informed con-
sent. All experiments were performed in accordance with the 
Committee’s guidelines. These sample sets have been de-
scribed in previous studies.6,18–20
Serum pyridoxal measurements
Serum pyridoxal levels were measured using high- 
performance liquid chromatography (HPLC). We used an 
acid phosphatase to hydrolyze phosphate-ester com-
pounds of pyridoxal. Next, we removed the protein using 
trichloroacetic acid. After adjusting the pH and using a 
 reversed-phase column, we carried out the fractionation of 
pyridoxal and measured natural fluorescence with a 
 spectrophotometer.
SNP genotyping
For genotyping, we used a commercially available TaqMan 
probe with an Applied Biosystems 7500 Fast Real-Time PCR 
System, according to the protocol recommended by the 
manu facturer (Applied Biosystems). The genotyping data of 
the Fujita Health University set was obtained from M. Ikeda 
(personal communication, Feb. 27, 2015), including previous 
GWAS data.19
Selection of studies for a meta-analysis of association 
 studies between serum pyridoxal levels and schizophrenia
Eligible studies were identified in PubMed and Science Direct 
using the search terms vitamin B6 and schizophrenia. Studies 
were included for further meta-analysis if they met the fol-
lowing criteria: included laboratory assessment of  serum pyr-
idoxal levels, performed a case– control study (schizophrenia 
v. control), measured serum pyridoxal level using HPLC, 
and published in English. Two reviewers (M.K. and Y.T.) se-
lected the articles independently according to the inclusion 
criteria. The scheme of the present study’s selection is shown 
in Appendix 1, Fig. S1. 
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Statistical analysis
Statistical analyses were performed with R software (ver-
sion 3.2.3). Raw serum pyridoxal data were natural log- 
transformed before calculations, as performed in a previous 
study,21 because raw values of serum pyridoxal concentra-
tions did not follow a Gaussian distribution. To validate the 
effect of rs4654748, which was identified in a previous 
GWAS,3 on serum pyridoxal levels in the Japanese control 
participants, we performed a multiple linear regression 
analy sis, adjusting for age and sex. The β coefficient value, 
which represents a one-unit change in the natural log- 
transformed serum pyridoxal levels per copy increment in 
the C allele of rs4654748, was calculated as performed in our 
previous study.8 We performed a stratified analysis to exam-
ine the presence of differences in natural log-transformed 
 serum pyridoxal levels between the 2 groups (schizophrenia 
v. control) separately by sex and by 3 genotypes of rs4654748 
(total of 6 strata) after adjusting for age. Meta-analyses of as-
sociation studies were performed on standardized mean dif-
ferences (SMD), as performed in our previous study.6 In the 
meta-analysis of genetic association studies, we considered 
the C allele of rs4654748 as a reference allele. Heterogeneity 
was assessed using the I2 statistic. If heterogeneity across 
studies was found, then we applied a random-effects model; 
otherwise, we applied a fixed-effects model. We assessed 
publication bias using funnel plots and a regression test.22 We 
performed MR analysis using rs4654748 as the instrumental 
variable, as undertaken in our previous studies.6,7 An esti-
mate for the C allele of rs4654748–serum pyridoxal level asso-
ciation was obtained from the present study of 859 Japanese 
control participants, as a β coefficient value (β pyridoxal/per 
allele). The risk estimate for an rs4654748–schizophrenia 
 association was obtained from a current meta-analysis of the 
Japanese genetic association studies, as an odds ratio (OR) 
schizophrenia/per allele. An MR estimate for the effect of 
pyridoxal levels on schizophrenia risk was calculated, as an 
OR schizophrenia/pyridoxal. We used the following equation: 
log OR schizophrenia/pyridoxal = (log OR schizophrenia/per allele)/ βpyridoxal/per allele.
Results
Effect of rs4654748 on serum pyridoxal levels  
in nonpsychiatric Japanese control participants
We examined whether the C allele of rs4654748, which was 
identified in an Italian GWAS,3 was associated with serum 
pyridoxal levels in nonpsychiatric Japanese controls. A linear 
regression analysis showed a significant effect of rs4654748 on 
serum pyridoxal levels in the Japanese population (β = –0.13, 
standard error [SE] 0.05, p = 0.006).
Differences in serum pyridoxal levels between participants 
with and without schizophrenia
Median serum pyridoxal levels in 365 patients with schizo-
phrenia and in 911 control participants were 4.4 ng/mL 
(range 2.0–91.1 ng/mL) and 8.9 (range 2.1–99.8 ng/mL), 
 respectively. When we conducted a linear regression analy-
sis to examine the effects of diagnosis, age, sex and the 
geno types of rs4654748 on serum pyridoxal levels, we 
found significant effects of diagnosis, sex and rs4654748 
genotype (diagnosis: p = 1.0 × 10–40; sex: p < 0.001; geno-
type: p < 0.001). A stratified analysis was performed to 
 examine differences in serum pyridoxal levels between the 
2 groups separately by sex and rs4654748 genotypes (a total 
of 6 strata), adjusting for age. A significant effect of diagno-
sis (lower in the schizophrenia group than in the control 
group) was observed in all strata (p < 0.006; Fig. 1). We did 
not detect pyridoxine and pyridoxamine (2 of the 3 forms 
of vitamin B6) in most participants. Among 1276 partici-
pants, 1248 exhibited a pyridoxine concentration below the 
lower limit of detection (3.0 ng/mL), and 1248 participants 
had a pyridoxamine concentration below the lower limit of 
detection (0.2 ng/mL).
Fig. 1: Differences in serum pyridoxal levels between patients with 
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A meta-analysis of case–control studies between serum 
pyridoxal levels and schizophrenia
We performed a meta-analysis of previous association  studies 
between serum pyridoxal levels and schizophrenia. The 
 studies included in this meta-analysis are shown in  Appendix 1, 
Table S2. We used 5 studies, including our data, for a total of 
840 patients with schizophrenia and 1285 control participants. 
An inverse-variance fixed-effects model showed that serum 
pyridoxal levels were significantly lower in patients with 
schizophrenia than in controls (SMD –0.48, 95% confidence 
 interval [CI] –0.57 to –0.39, p = 9.8 × 10–24); heterogeneity was 
not observed among studies (I2 = 0%, p > 0.99; Fig. 2). A fun-
nel plot analysis indicated no evidence of a publication bias in 
the association studies (p = 0.76; Appendix 1, Fig. S2).
A meta-analysis of genetic association studies between 
rs4654748 and schizophrenia
We examined whether the C allele of rs4654748, which is asso-
ciated with decreased pyridoxal levels, was a risk factor for 
schizophrenia in the Japanese population by conducting gen-
etic association studies in 4 independent sample sets. The 
 average genotype call rate was 99.5%, and the genotype con-
cordance rate of 96 duplicate samples was 100%. The geno-
typic distributions of rs4654748 did not deviate significantly 
from Hardy–Weinberg equilibrium in the control group in all 
sample sets (all p > 0.05). No significant diagnostic differences 
were observed in the genotypic and allelic frequencies in 
these sample sets (all p > 0.05; Appendix 1, Table S3). Subse-
quently, we performed a meta-analysis of these 4 genetic asso-
ciation studies for a total of 4624 cases and 6010 controls. We 
observed no significant diagnostic differences in any genetic 
model (all p > 0.05; Appendix 1, Table S4), and no heterogen-
eity was noted among studies (all I2 = 0%, all p > 0.05).
Causality between serum pyridoxal levels and 
 schizophrenia in a Mendelian randomization analysis
The βpyridoxal/per allele from the current association study between 
rs4654748 and serum pyridoxal levels in Japanese control 
participants (n = 859) was –0.13 (SE 0.05, p = 0.006). The esti-
mated ORschizophrenia/per allele from the current meta-analysis of the 
Japanese genetic association studies between rs4654748 and 
schizophrenia (n = 10 634) was 1.00 (95% CI 0.95–1.06, p = 
0.96). The estimated ORschizophrenia/pyridoxal calculated by combining 
the β pyridoxal/per allele and the ORschizophrenia/per allele were not 
significant, representing the OR of 0.99 (95% CI 0.65–1.51, p = 
0.96; Fig. 3). When we calculated the estimated ORschizophrenia/pyridoxal 
by combining the pooled GWAS data sets, the βpyridoxal/per allele 
from a meta-analysis of pyridoxal GWAS (n = 1864),3 and 
the ORschizophrenia/per allele from a meta-analysis of schizophrenia 
GWAS (n = 150 064),23 we obtained the same result 
(ORschizophrenia/pyridoxal 0.99, 95% CI 0.98–1.01, p = 0.28).
Association between pyridoxal and homocysteine
We examined the association between serum pyridoxal and 
plasma total homocysteine using our previous study’s homo-
cysteine data.6 Although there was an inverse correlation 
Fig. 2: Meta-analysis of case–control studies between serum pyridoxal levels and schizophrenia. CI = confidence interval; FE = 
fixed-effects; SMD = standardized mean difference.
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 between pyridoxal and homocysteine in the schizophrenia 
group (r = –0.11, p = 0.043), we did not find a significant in-
verse correlation between these variables in the control 
group (r = –0.06, p = 0.09).
Discussion
In this study, we first replicated an association between 
 serum pyridoxal levels and rs4654748, which was identified 
in an Italian GWAS, in Japanese control participants. Next, 
we showed that serum pyridoxal levels were lower in the 
schizophrenia group than in the control group, with sex and 
rs4654748 genotype being other independently associated 
factors in the Japanese population. To our knowledge, this is 
the first case–control study separated by sex and by genotype 
associated with vitamin B6. Subsequently, we confirmed de-
creased serum pyridoxal levels in patients with schizophre-
nia by conducting a meta-analysis of association studies be-
tween serum pyridoxal levels and the disorder. This is also, 
to our knowledge, the first meta-analysis of cross-sectional 
studies of serum pyridoxal levels in schizophrenia. Our find-
ings were consistent with the results of previous studies.12–15
Investigating causalities between serum pyridoxal levels 
and schizophrenia is important for understanding schizo-
phrenia pathology and treatment. To our knowledge, this is 
the first MR study to examine the causal role of pyridoxal 
levels in schizophrenia. We evaluated the effect of long-term 
pyridoxal on schizophrenia by using a genetic variant associ-
ated with pyridoxal as an instrumental variable. We failed to 
obtain data supporting a causal relationship between de-
creased pyridoxal levels and schizophrenia risk in the 
 Japanese population, as well as in the pooled GWAS data 
sets. Recently, we reported evidence of a causal relationship 
between elevated blood homocysteine levels and schizophre-
nia risk.6,7 When we examined the associations between 
plasma total homocysteine and serum pyridoxal levels in 
participants with schizophrenia and found a negative cor-
relation between these 2 variables. These results suggest that 
decreased pyridoxal levels observed in patients with schizo-
phrenia may be the result of the increased total homocysteine 
levels observed in indivdiuals with this disorder.
However, the absence of causality between serum pyri-
doxal levels and schizophrenia in our MR analysis must still 
be viewed with caution because several clinical studies have 
indicated that vitamin B6 may be involved in schizophrenia 
pathology and treatment. For example, Miyashita and col-
leagues24 identified a negative correlation between serum 
pyri doxal levels and symptom severity in patients with 
chronic schizophrenia. Katsuta and colleagues13 showed in a 
longitudinal study that decreased serum pyridoxal levels in 
patients with acute schizophrenia were normalized according 
to the clinical course, and the patients with decreased serum 
pyridoxal levels during the clinical course showed less im-
provement in symptoms. Furthermore, several previous 
 studies reported the therapeutic effect of pyridoxine (1 of the 
3 forms of vitamin B6) in patients with schizophrenia,25–30 al-
though other studies, including a meta-analysis of random-
ized controlled trials of vitamin B6 alone,31 have not provided 
evidence of the benefits of pyridoxine in people with this dis-
order.32,33 These results suggest that pyridoxine may be effec-
tive for a particular subpopulation of patients with schizo-
phrenia, but not for general schizophrenia populations.
Interestingly, a meta-analysis of randomized controlled 
trials showed that pyridoxal 5 phosphate (the active form of 
vitamin B6) may be effective in treating tardive dyskinesia 
in individuals with schizophrenia.34 Furthermore, the po-
tential efficacy of vitamin B6 in the treatment of acute 
 neuroleptic-induced akathisia and lithium-induced tremor 
Fig. 3: Mendelian randomization analysis. CI = confidence interval; OR = odds ratio; SD = standard deviation; SE = standard error.
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has been reported.35–37 These results suggest that vitamin B6 
may be involved in a broad spectrum of movement disorders.38
Limitations
Our study has several limitations that should be men-
tioned. First, most patients were treated with various anti-
psychotic drugs, and these medications may have influ-
enced the results. However, we did not find any 
correlations between equivalent dose and serum pyridoxal 
levels in participants with schizophrenia, which is consis-
tent with the findings of a previous study.13 Second, the 
blood samples used in the study were collected when 
 patients visited the hospital; therefore, we cannot rule out 
that food consumption may have affected serum pyridoxal 
levels. Third, we did not take potential confounding fac-
tors, such as body mass index and metabolic parameters, 
into consideration in our analysis owing to lack of data. 
Additionally, limitations existed in our MR analysis, in-
cluding sample size, a small proportion of variance in 
 serum pyridoxal levels explained by rs4654748 (0.89%), and 
only 1 SNP that was used as an instrumental variable. 
Fifth, we performed the experiments on the participants 
with schizophrenia defined according to DSM-IV. Broader 
approaches, such as endophenotypes or dimensional syn-
drome models may be needed. Finally, we focused on pyri-
doxal concentrations in patients with schizophrenia in the 
present study. Vitamin B6 is a key component in one- 
carbon metabolism (Appendix 1, Fig. S3), and several com-
ponents in one-carbon metabolism have been implicated in 
schizophrenia.4,5 An extensive systematic investigation of 
one-carbon metabolism will be needed to reveal the com-
plex pathophysiology of schizophrenia.
Conclusion
We found decreased serum pyridoxal levels in patients 
with schizophrenia in this observational study. However, 
we failed to obtain data supporting a causal relationship 
between pyridoxal levels and schizophrenia using the MR 
approach. Further large studies, such as longitudinal epi-
demiological studies and randomized controlled trials, will 
be needed in the future.
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Indications and Clinical Use: 1
FOQUEST® is indicated for the treatment of Attention-Deficit Hyperactivity 
Disorder (ADHD) in adults (≥18 years of age). FOQUEST is indicated as an 
integral part of a total treatment program for ADHD that may include other 
measures (psychological, educational and/or social) for patients with this 
syndrome. FOQUEST has not been studied in the geriatric population 
(>65 years of age). The effectiveness of FOQUEST has been evaluated for 
more than four weeks in placebo-controlled clinical trials.  If electing to 
use FOQUEST for extended periods, the long-term usefulness of the drug 
for the individual patient should be periodically re-evaluated.  
Contraindications: 1
• Known hypersensitivity or idiosyncrasy to sympathomimetic amines
• Patients with anxiety, tension, agitation
• Thyrotoxicosis
• Advanced arteriosclerosis
• Symptomatic cardiovascular disease
• Moderate to severe hypertension
• Glaucoma
• Patients with a history of drug abuse
• Patients with motor tics or with a family history or diagnosis 
   of Tourette’s syndrome (verbal tics)
• During or within 14-days following the administration of 
   monoamine oxidase inhibitors (hypertensive crises may result)
Most Serious Warning and Precaution: 1
• Drug dependence/tolerance. FOQUEST should be given   
   cautiously to emotionally unstable patients. Careful supervision 
   is  required during withdrawal. 
Other Relevant Warnings and Precautions: 1
• Caution in patients who: are involved in strenuous exercise 
   or activities, use other stimulants, or have a family history of 
   sudden/cardiac death.  
• Sudden death, stroke, and myocardial infarction. 
• CNS stimulants should be used with caution in patients with 
   a condition of the cardiovascular or cerebrovascular system. 
• Hypertension. 
• Alcohol should not be taken with FOQUEST. 
• Increase in seizure frequency. 
• Onset or exacerbation of motor and verbal tics.  
• Impairment in ability to operate machinery or vehicles. 
• Visual disturbances.  
• Psychiatric effects: Not for treatment of depression; not for use in 
   treatment or prevention of normal fatigue states; may exacerbate   
   psychosis symptoms in patients with pre-existing psychotic
   disorder; screen for risk of bipolar disorder in patients with 
   comorbid depressive symptoms; monitor patients for signs of 
   suicide-related behaviour; monitor patients for new psychotic or 
   manic episodes and aggressive behaviour. 
• The concomitant use of methylphenidate and serotonergic drugs 
   is not recommended. 
• Priapism. 
• Peripheral vasculopathy, including Raynaud’s phenomenon. 
• Not given to pregnant women unless the potential benefit  
   outweighs the risk to the fetus. 
• Either abstain from breast-feeding or abstain from FOQUEST therapy, 
   taking into account the benefit of breast-feeding to the child and the 
   benefit of therapy to the woman. 
• Periodic laboratory tests are advised during prolonged therapy. 
For more information:
Please consult the Product Monograph at http://purdue.ca/en/products/
Foquest-PM for important information relating to adverse reactions, 
drug interactions, and dosing information which have not been 
discussed in this piece. The Product Monograph is also available by 
calling us at 1-800-387-5349.
Reference: 1. CFOQUEST® Product Monograph, Purdue Pharma, 
December 5, 2017.
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